Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share. The company specializes in the development of therapies for sickle cell anemia. The sales volume of Oxbryta, created by GBT, reached $195 million in 2021. Pfizer intends to accelerate Oxbryta distribution in the regions of the world most affected by sickle cell anemia.